Earnings per share actually fell year-over-year despite the beat
In the quiet arithmetic of institutional repositioning, MetLife Investment Management trimmed its stake in Bio-Rad Laboratories by a modest 1.4% during the first quarter of 2025 — a small move that nonetheless reflects the measured caution large investors exercise when a company's fundamentals tell two stories at once. Bio-Rad, a foundational supplier to the life sciences world, beat quarterly earnings expectations by a wide margin yet saw its year-over-year profits decline, leaving analysts and shareholders to weigh present strength against uncertain trajectory. The company's essential role in proteomics, genomics, and diagnostic research ensures it will remain watched closely, but the mixed signals from institutional activity and analyst revisions suggest the market is still deciding what Bio-Rad's next chapter looks like.
- Bio-Rad beat Q2 earnings estimates by nearly 35% — $2.61 EPS against an expected $1.93 — yet the same metric had stood at $3.11 a year earlier, creating an uncomfortable contradiction at the heart of the story.
- MetLife's quiet sale of 153 shares may be numerically small, but when one of the world's largest institutional investors steps back, even gently, the market pays attention.
- Other institutional players moved in opposite directions — Allworth Financial expanded its position by 260%, while new entrants like Skylands Capital and Curat Global established fresh stakes, signaling no consensus on the stock's direction.
- Analyst ratings have grown more cautious, with Wall Street Zen downgrading to 'hold' and Wells Fargo assigning 'equal weight,' even as Royal Bank of Canada raised its target to $409 with an 'outperform' call.
- The stock trades at $298.39 — well below the average analyst target of $333.50 — leaving open the question of whether the gap represents opportunity or a warning that targets themselves may drift lower.
MetLife Investment Management sold 153 shares of Bio-Rad Laboratories in the first quarter of 2025, reducing its stake by 1.4% to 10,695 shares valued at roughly $2.6 million. The move was small in absolute terms but carries symbolic weight — when major institutional investors quietly reposition, it often reflects a recalibration of confidence rather than a dramatic change of view.
Bio-Rad manufactures instruments, reagents, and diagnostic systems used across life science research and clinical diagnostics, operating in the United States, Europe, Asia, and Latin America. Its products underpin modern genomics, proteomics, and biopharmaceutical research, making institutional appetite for the stock a meaningful signal about sentiment in the broader life sciences sector.
Not all institutional investors followed MetLife's lead. Allworth Financial expanded its holdings by 260%, and Headlands Technologies increased its position by 64%. New positions were opened by Skylands Capital and Curat Global, while Mackenzie Financial had already built a stake in the prior quarter. Collectively, institutional investors and hedge funds control 65.24% of Bio-Rad's shares, meaning the company's market story is largely written by these large players moving in different directions.
Bio-Rad's most recent earnings report offered genuine cause for optimism: the company reported $2.61 EPS against an expected $1.93, and revenue of $651.6 million exceeded estimates by a meaningful margin. The balance sheet is healthy, with a low debt-to-equity ratio and strong liquidity. The complication lies in the comparison — a year earlier, EPS had been $3.11, meaning the company beat expectations while still declining on a year-over-year basis.
Analyst sentiment has grown more divided in response. Royal Bank of Canada raised its target to $409 with an outperform rating, while Wells Fargo lifted its target but assigned only equal weight. Wall Street Zen downgraded the stock to hold in late August, and Zacks moved it from strong sell to hold — technically an upgrade, but hardly an endorsement. The consensus settles at a 'Moderate Buy' with a $333.50 average target, against a current trading price of $298.39.
What the full picture reveals is a company that is performing adequately but not inspiring conviction. MetLife's modest pullback, the year-over-year earnings decline, and the cautious analyst revisions together suggest that institutional investors are pausing to reassess — waiting to see whether Bio-Rad's quarterly beat represents a turning point or a temporary reprieve before a more difficult reckoning.
MetLife Investment Management LLC trimmed its stake in Bio-Rad Laboratories during the first quarter of 2025, selling 153 shares and leaving the firm with 10,695 shares valued at $2.61 million. The move, while modest in percentage terms—a 1.4% reduction—signals a subtle shift in how one of the world's largest institutional investors views the medical research company. It's the kind of quiet repositioning that often goes unnoticed but speaks volumes about confidence levels in the market.
Bio-Rad, which manufactures and distributes life science research and clinical diagnostic products across the United States, Europe, Asia, Canada, and Latin America, operates through two main divisions: Life Science and Clinical Diagnostics. The company develops instruments, systems, reagents, and consumables used to separate, purify, and analyze biological materials—work that sits at the foundation of modern proteomics, genomics, and biopharmaceutical research. It's essential infrastructure for the life sciences world, which makes institutional appetite for the stock worth watching.
The broader picture of institutional activity around Bio-Rad reveals mixed signals. While MetLife was pulling back, other investors were moving in different directions. Curat Global LLC and Skylands Capital LLC both established new positions in the first quarter, with Skylands committing roughly $122,000. Allworth Financial LP expanded its holdings by 260 percent, acquiring an additional 104 shares to bring its total to 144 shares worth $36,000. Headlands Technologies LLC increased its position by 64.1 percent, adding 139 shares for a total stake valued at $87,000. Mackenzie Financial Corp, meanwhile, had already built a new position in the fourth quarter worth approximately $207,000. Institutional investors and hedge funds collectively own 65.24 percent of Bio-Rad's stock, meaning the company's direction is largely shaped by these large players.
The company's recent earnings report offered reasons for optimism. In the quarter ending July 31st, Bio-Rad reported earnings per share of $2.61, beating analyst expectations of $1.93 by a substantial margin. Revenue came in at $651.6 million, also exceeding the consensus estimate of $614.82 million and representing 2.1 percent year-over-year growth. The company maintains a healthy balance sheet with a debt-to-equity ratio of 0.17 and a current ratio of 5.12, suggesting strong liquidity. Yet there's a complication: earnings per share in the same quarter a year earlier had been $3.11, meaning the company's bottom line actually declined on a year-over-year basis despite the beat on expectations.
Analyst sentiment has grown more cautious in recent weeks. Royal Bank of Canada lifted its target price from $387 to $409 and maintained an "outperform" rating. Wells Fargo raised its target from $245 to $265 but assigned an "equal weight" rating, suggesting limited upside. Wall Street Zen downgraded the stock from "buy" to "hold" on August 22nd. Zacks Research upgraded Bio-Rad from "strong sell" to "hold" on August 26th—technically positive movement, but still not a ringing endorsement. The consensus among three buy ratings and two hold ratings yields a "Moderate Buy" rating overall, with an average target price of $333.50. The stock opened at $298.39 on Monday, trading up 1.6 percent, with a 52-week range of $211.43 to $387.99.
What emerges from this snapshot is a company that has delivered on its numbers but faces investor uncertainty about its trajectory. MetLife's modest reduction, combined with the mixed analyst commentary and the year-over-year earnings decline, suggests that even as Bio-Rad beats quarterly expectations, institutional investors are recalibrating their bets. The company carries a market capitalization of $8.07 billion and trades at a P/E ratio of 25.44, with analysts projecting full-year 2025 earnings of $10.81 per share. Whether that projection holds, and whether the recent analyst downgrades signal the beginning of a broader retreat or merely a pause in enthusiasm, will likely determine whether MetLife's pullback looks prescient or premature.
Notable Quotes
Bio-Rad reported earnings per share of $2.61, beating analyst expectations of $1.93 by a substantial margin— Company earnings report, July 31, 2025
Institutional investors and hedge funds own 65.24 percent of the company's stock— SEC filings and institutional holdings data
The Hearth Conversation Another angle on the story
Why would MetLife reduce a position in a company that just beat earnings expectations?
Because beating expectations and having momentum are different things. Bio-Rad's earnings per share actually fell year-over-year, from $3.11 to $2.61. They beat the consensus estimate, but that consensus had been lowered. MetLife might be reading that as a sign the company is slowing.
So the stock is expensive relative to its growth?
At a P/E of 25.44, it's not cheap. And when you're growing revenue only 2.1 percent year-over-year, that multiple starts to feel stretched. MetLife is a long-term holder, not a trader. They don't make emotional moves. A 1.4 percent reduction is their way of saying, "We're watching this."
But other investors are buying. Doesn't that contradict the MetLife signal?
Not necessarily. Some of those new positions are small—Curat Global's $34,000 stake is almost nothing. Allworth and Headlands are increasing positions, sure, but they're also small players. The real money—institutional investors owning 65 percent of the stock—is the one that matters. And that money is mixed.
What do the analysts actually think?
They're hedging. Royal Bank of Canada says "outperform" but Wells Fargo says "equal weight." Wall Street Zen went from buy to hold. Zacks upgraded from strong sell to hold, which sounds positive until you realize hold means "don't expect much." The consensus is "Moderate Buy" with a $333.50 target, but the stock is at $298. That's not a lot of upside.
Is this a company in trouble?
No. The balance sheet is solid, the business is real, and they're profitable. But they're also mature. Life sciences research is growing, but not explosively. Bio-Rad is a steady business, not a growth story anymore. MetLife's pullback is just them acknowledging that reality.
So what happens next?
Watch whether the other institutional money keeps flowing in or starts to dry up. If MetLife's caution spreads, you'll see more trimming. If Bio-Rad can accelerate revenue growth and prove the earnings decline was temporary, the stock could re-rate higher. Right now, it's in a holding pattern.